Search bioRxiv⌕ Search

Biology subjects

Honsho, M.

Publications and source records attributed to Honsho, M..

3 recordsLinked to original sources

Plasmalogen-Independent Neuroprotection: Synthetic alkyl ether lipids activate signaling to mitigate neuroinflammation and enhance cognitive function

Neuroinflammation is a key driver of neurodegenerative disorders, with chronic activation of the NF-{kappa}B pathway contributing to neuronal dysfunction and disease progression. In this study, we report that KIT-8, a synthetic alkyl ether lipid, exerts potent anti-inflammatory and neuroprotective effects despite its inability to be converted into plasmalogens within cells unlike its analog KIT-13, which is known to generate plasmalogens. Remarkably, KIT-8 activates key intracellular signaling pathways, including phosphorylation of ERK and AKT, and enhances brain-derived neurotrophic factor (Bdnf) expression in Neuro2A cells, thereby mimicking the actions of both KIT-13 and natural plasmalogens. Furthermore, KIT-8 significantly improves memory function in mice, underscoring its inherent therapeutic potential. Importantly, the biological activity of KIT-8 suggests that plasmalogen synthesis is not required for its functional effects, introducing a novel concept in ether lipid biology. Supporting this notion, we identified additional alkyl ether lipid analogs, KIT-19 and KIT-20, which also demonstrated anti-inflammatory properties despite lacking the ability to generate plasmalogens. These findings indicate that the ether bond structure alone may be sufficient to confer biological activity. To explore this further, we designed and synthesized a series of structurally distinct alkyl ether lipids (KIT compounds) retaining an ether bond at the sn-2 position. In an LPS-induced inflammatory model using mouse-derived microglial MG6 cells, selected compounds KIT-8, KIT-19, and KIT-20 significantly suppressed NF-{kappa}B signaling, reduced p65 nuclear translocation, and downregulated the expression of pro-inflammatory mediators IL-1{beta} and NOS2. Given the cognitive benefits associated with plasmalogens in Alzheimers disease, our findings position alkyl ether lipids as promising standalone bioactive molecules, capable of mitigating neuroinflammation and enhancing neuronal function independently of plasmalogen synthesis.

neuroscience↗

Novel plasmalogen derivative KIT-13 restores neurological function in a mouse model of Rett syndrome by reducing neuroinflammation and restoring mitochondrial function

Neurodevelopmental disorders, including Rett Syndrome (RTT), have no functional cure and cause substantial levels of disability. Neuroinflammation is now strongly associated with both neurodevelopmental disorders and neurodegenerative diseases, providing a strong rationale for development of novel therapeutics targeting common neuroinflammatory mechanisms. RTT is caused by mutations in the methylated DNA binding factor MECP2. Mecp2-deficient (Mecp2-KO) mice, which have been extensively characterized as a mouse model of RTT, exhibit high levels of neuroinflammation, mitochondrial dysfunction, and severe neurological symptoms similar to RTT patients. KIT-13 is a novel plasmalogen derivative being developed for the treatment of neurodevelopmental disorders including RTT. This study evaluated KIT-13 in both cell-based and in vivo models for its potential to inhibit neuroinflammation and address underlying mitochondrial dysfunction, as well as effects on RTT-like neurological symptoms in the RTT mouse model. Oral administration of KIT-13 to Mecp2-KO mice significantly reduced neurological symptoms assessed by a composite score evaluating mobility, gait, hindlimb clasping, tremor, breathing, and general condition and improved the life span of the RTT model mice. In addition, KIT-13 suppressed mitochondrial DNA leakage associated with Mecp2 deficiency, and significantly suppressed neuroinflammation as measured by microglial cell morphology. These results suggest that KIT-13 may be a promising therapeutic agent for RTT and other neuroinflammation-related diseases.

neuroscience↗

An alternative membrane topology permits lipid droplet localization of peroxisomal fatty acyl-CoA reductase 1

Fatty acyl-CoA reductase 1 (Far1) is an ubiquitously expressed peroxisomal membrane protein generating fatty alcohols required for the biosynthesis of ether lipids.\n\nLipid droplet localization of human Far1 was observed by fluorescence microscopy under conditions of increased triglyceride synthesis in tissue culture cells. This unexpected finding was supported further by correlative light electron microscopy and subcellular fractionation. Selective permeabilization and N-glycosylation tagging suggest that Far1 is able to assume two different membrane topologies, differing in the orientation of the short hydrophilic C-terminus towards the lumen or the cytosol, respectively. Two closely spaced hydrophobic domains are contained within the C-terminal region. When analyzed separately, the second domain was sufficient for the localization of a fluorescent reporter to lipid droplets. Targeting of Far1 to lipid droplets was not impaired in either pex19 or TRC40/ASNA1 CRISPR/Cas9 knockout cells.\n\nIn conclusion, our data suggest that Far1 is a novel member of the rather exclusive group of dual topology membrane proteins. At the same time, Far1 shows lipid metabolism-dependent differential subcellular localizations to peroxisomes and lipid droplets.

cell biology↗